Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.42 |
| ▸ | RAB9A | P51151 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307353 | 0.78 | MAPT (0.44) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL2123728 | 0.77 | NPC1 (0.42) | IDO1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL2122470 | 0.77 | IDO1 (0.42) | IDO1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2122676 | 0.77 | IDO1 (0.42) | IDO1NPC1RAB9ASMN1; SMN2TP53 | |
| SCHEMBL2121002 | 0.73 | NOTUM (0.42) | TSHRCYP1A2CYP2C19NOTUMCYP3A4 | |
| SCHEMBL2122409 | 0.73 | METAP2 (0.46) | NPC1RAB9ASMN1; SMN2TP53HPGD | |
| SCHEMBL10885522 | 0.72 | NPC1 (0.40) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL346163 | 0.69 | NOTUM (0.42) | NPC1RAB9ASMN1; SMN2CYP1A2MAPT | |
| SCHEMBL2123730 | 0.69 | ALDH1A1 (0.47) | NPC1RAB9ASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL3937636 | 0.69 | AHR (0.48) | NPC1RAB9ASMN1; SMN2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696181-B2 | Partial and full agonists of A1 adenosine receptors | CV THERAPEUTICS, INC. (US) | 2010-04-13 | — | — | US | claimed |
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | IBRAHIM PRABHA | 2009-12-31 | — | — | US | claimed |
| US-7521453-B2 | e.g. 5-Bromo-2-(3-methylisoxazol-5-ylmethylamino)-4-(5-cyclopropyl- 1H-pyrazol-3-ylamino)pyrimidine; anticarcinogenic, antitumor agents; breast, prostate, colon cancer | ASTRAZENECA AB (SE) | 2009-04-21 | — | — | US | claimed |
| EP-1456182-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2009-03-11 | — | — | EP | claimed |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | IBRAHIM PRABHA | 2006-12-21 | — | — | US | claimed |
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | claimed |
| US-20050288336-A1 | Cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | US | claimed |
| EP-1569954-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | claimed |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | ASTRAZENECA AB | 2005-03-10 | — | — | US | claimed |
| EP-1503997-A1 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-02-09 | — | — | EP | claimed |
| EP-1456182-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | AstraZeneca AB (SE) | 2004-09-15 | — | — | EP | claimed |
| WO-2004052921-A1 | CYANOMETHYL DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-24 | — | — | WO | claimed |
| WO-2003097617-A1 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | claimed |
| WO-2003048133-A1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) | ASTRAZENECA AB (SE) | 2003-06-12 | — | — | WO | claimed |
| US-20200045972-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-02-13 | — | — | US | disclosed |
| US-8765791-B2 | Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| CN-102014900-B | Method of treating cancer using a neuropeptide Y5R (NPY5R) antagonist | UNIV HEALTH NETWORK | 2014-04-02 | — | — | CN | disclosed |
| WO-2001014376-A1 | NOVEL SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
| US-4203896-A | WITH MERCURIC ACETATE AND ACETIC ACID, ACIDIC HYDROLYSIS OF N-PROPENYL GROUP | ELI LILLY AND COMPANY (US) | 1980-05-20 | — | — | US | disclosed |
| US-4144232-A | Substituted azetidin-2-one antibiotics | ELI LILLY AND COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325896-A1 | PARTIAL AND FULL AGONISTS OF A1 ADENOSINE RECEPTORS | ADORA1, ADORA2A, ADORA3 | IDO1 2242/4885NPC1 400/4885RAB9A 2024/4885 |
| US-20060287275-A1 | Partial and full agonists of A1 adenosine receptors | ADORA1, ADORA2A, ADORA3 | IDO1 2242/4885NPC1 400/4885RAB9A 2024/4885 |
| US-20060122184-A1 | Cyanomethyl derivatives as cysteine protease inhibitors | CTSF, CTSB, CTSK | IDO1 2583/4885NPC1 627/4885RAB9A 2196/4885 |
| US-20200045972-A1 | NOVEL 5-SUBSTITUTED IMIDAZOLYLMETHYL DERIVATIVES | IPMK, PIP5K1B, PIP5K1C | IDO1 140/4885NPC1 4288/4885RAB9A 1860/4885 |
| US-20050288336-A1 | Cysteine protease inhibitors | CTSF, CTSS, CTSB | IDO1 3593/4885NPC1 246/4885RAB9A 1046/4885 |
| US-20050054638-A1 | Pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (igf-i) | IGF1R, IGFBP1, INSR | IDO1 739/4885NPC1 4365/4885RAB9A 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.